Ray Dalio
CNMD icon

Ray Dalio’s CONMED CNMD Stock Holding History

Ray Dalio’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,933
Closed -$279K – 1080
2025
Q3 		$279K Buy
+5,933
New +$308K ﹤0.01% 975

Other funds holding CNMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return

Ray Dalio's CNMD Position: Q4 2025 in Review

Ray Dalio sold out of CONMED (CNMD) in Q4 2025, closing a stake of 5,933 shares — an estimated $279K sold.

Ray Dalio first reported a position in CNMD in Q3 2025 and held it in 1 quarter. The position peaked at $279K in Q3 2025. 265 funds tracked by Wall St. Rank hold CNMD as of Q4 2025.

  • Ray Dalio reported no remaining CONMED position as of Q4 2025 after selling out during the quarter.
  • Ray Dalio sold 5,933 CONMED shares in Q4 2025, an estimated $279K.
  • Ray Dalio first reported a position in CONMED in Q3 2025 and held it in 1 quarter.
  • Ray Dalio's CONMED position peaked at $279K in Q3 2025.
  • 265 funds tracked by Wall St. Rank held CONMED as of Q4 2025.

Based on Bridgewater Associates's 13F filing for Q4 2025, filed 13 Feb 2026.